Cyclacel Pharma to Offer New Sapacitabine Data at ASH on Dec. 9th

Cyclacel Pharmaceuticals, Inc. CYCC CYCCP (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders announced today that updated Phase 3 clinical trial results for the treatment of elderly patients with newly diagnosed acute myeloid leukemia (AML) treated with sapacitabine and decitabine administered in alternating cycles will be presented at a poster presentation during the 54^th Annual Meeting of the American Society of Hematology (ASH) in Atlanta, on Sunday, December 9, 2012. The poster's abstract details are as follows: Abstract: 2630 Pooled Analysis of Elderly Patients with Newly Diagnosed AML Title: Treated with Sapacitabine and Decitabine Administered in Alternating Cycles Date/Time: Sunday, December 9, 2012, 6:00 PM - 8:00 PM Eastern Time   Hall B1-B2, Level 1, Building B (Georgia World Congress Center) Session: Acute Myeloid Leukemia - Therapy, excluding Transplantation: Poster II     Poster board: The abstract is available online at: https://ash.confex.com/ash/2012/webprogram/start.html.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!